• Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is facing a potential downside of -21.47%, indicating a pessimistic outlook from analysts.
• GeoVax Labs, Inc. (GOVX) and Senti Biosciences, Inc. (SNTI) also show negative growth potential, though less severe than TTNP.
• Processa Pharmaceuticals, Inc. (PCSA) and Third Harmonic Bio, Inc. (THRD) present positive growth potentials, contrasting with TTNP's negative outlook.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is a biopharmaceutical company focused on developing therapeutics for serious medical conditions. Currently, TTNP is trading at $4.01, with a target price of $3.15, suggesting a potential downside of -21.47%. This indicates a pessimistic outlook from investment analysts, who foresee a decline in the stock's value.

In comparison, GeoVax Labs, Inc. (GOVX) is trading at $0.9292 with a target price of $0.7892, reflecting a potential downside of -15.07%. With a market cap of $12.86 million, GOVX shares a similar negative growth outlook with TTNP, though slightly less severe.

Senti Biosciences, Inc. (SNTI) presents a more moderate negative growth potential of -7.69%, with its current price at $3.45 and a target price of $3.18. Despite this, SNTI's market cap of $89.98 million suggests a more stable position compared to TTNP.

On the other hand, Processa Pharmaceuticals, Inc. (PCSA) and Third Harmonic Bio, Inc. (THRD) show positive growth potentials of 29.77% and 31.40%, respectively. PCSA's current price is $0.2815, with a target of $0.3653, while THRD is trading at $5.14, with a target of $6.75. These figures indicate a more optimistic outlook for these companies.

Indaptus Therapeutics, Inc. (INDP) stands out with the highest growth potential among TTNP's peers, at 41.75%. With a current price of $0.43 and a target price of $0.61, INDP offers a significant upside, making it an attractive option for investors seeking growth opportunities in the sector.